PMID- 15819169
OWN - NLM
STAT- MEDLINE
DCOM- 20050729
LR  - 20111117
IS  - 1433-6510 (Print)
IS  - 1433-6510 (Linking)
VI  - 51
IP  - 3-4
DP  - 2005
TI  - Stability of insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-3 
      measured by the IMMULITE automated chemiluminescence assay system in different 
      blood specimens.
PG  - 145-52
AB  - Insulin-like growth factor I (IGF-I) and IGF binding protein 3 (IGFBP-3) are 
      measured to diagnose disorders of the somatotropic axis in children and adults. 
      In clinical studies samples for IGF-I and IGFBP-3 measurement must often be 
      stored for months and sent to specialized laboratories. Therefore, we tested the 
      stability of IGF-I and IGFBP-3 in whole blood, serum and plasma from 12 
      volunteers at 4 degrees, 22 degrees, and 37 degrees C for several hours and at 
      -25 degrees C for several months. The effect of only one protease inhibitor 
      (Aprotinin = Trasylol, Bayer, Germany ) on IGF-I and IGFBP-3 measured in the 
      automated IMMULITE assay system (DPC, Los Angeles) was tested. IGF-I and IGFBP-3 
      were stable in heparinized whole blood, plasma and serum at 22 degrees C up to 24 
      hours. IGF-I was stabilized by aprotinin for up to 72 hours at 37 degrees C. 
      Factor concentrations were not altered after storage at -25 degrees C for at 
      least 12 months. Recognition of IGFBP-3 fragments by the antibody used in the 
      automated IGFBP-3 IMMULITE was excluded by measurement in 26 sera from pregnant 
      women which usually contain IGFBP-3 fragments. In conclusion, samples for 
      measurement of IGF-I and IGFBP-3 should be kept on ice and cooled if shipment 
      takes more than 48 hours or alternatively 5000 IU/ml aprotinin should be added. 
      IMMULITE assays are also valid to measure IGF-I and IGFBP-3 after at least 12 
      months storage at -25 degrees C.
FAU - Elmlinger, Martin W
AU  - Elmlinger MW
AD  - Pediatric Endocrinology, Children's Hospital, University of Tuebingen, Germany. 
      martin.elmlinger@altanapharma.com
FAU - Zwirner, Manfred
AU  - Zwirner M
FAU - Kuhnel, Werner
AU  - Kuhnel W
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Clin Lab
JT  - Clinical laboratory
JID - 9705611
RN  - 0 (Insulin-Like Growth Factor Binding Protein 3)
RN  - 0 (Serine Proteinase Inhibitors)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
RN  - 9087-70-1 (Aprotinin)
SB  - IM
MH  - Aprotinin/pharmacology
MH  - *Blood Specimen Collection
MH  - Female
MH  - Humans
MH  - Immunoassay/instrumentation/*methods
MH  - Insulin-Like Growth Factor Binding Protein 3/*blood
MH  - Insulin-Like Growth Factor I/*analysis
MH  - Luminescent Measurements/instrumentation/*methods
MH  - Pregnancy
MH  - Refrigeration
MH  - Serine Proteinase Inhibitors/pharmacology
EDAT- 2005/04/12 09:00
MHDA- 2005/07/30 09:00
CRDT- 2005/04/12 09:00
PHST- 2005/04/12 09:00 [pubmed]
PHST- 2005/07/30 09:00 [medline]
PHST- 2005/04/12 09:00 [entrez]
PST - ppublish
SO  - Clin Lab. 2005;51(3-4):145-52.